Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/14/2026

1. ORCL
2. NVDA
3. SPY
4. DFTX
5. AZN
6. USO
7. SRRK
8. LYNX
9. CGEM
10. SATL

Go back to Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
Lilly (Eli) & Co. (NYSE: LLY) Delayed: 1140.20 +24.50 (2.20%)
Previous Close $1115.70    52 Week High $88.16 
Open $1142.20    52 Week Low $67.88 
Day High $1153.95    P/E 263.94 
Day Low $1130.50    EPS $4.32 
Volume 628,327